/manager/Index ${session.getAttribute("locale")} 5 Influence of the selenium level on overall survival in lung cancer /manager/Repository/uon:37060 69 µg/L, reference). The 80 months crude survival after diagnosis was 79.5% (95% CI: 68.5-92.4%) for individuals in the highest tertile and 58.1% (95% CI: 45.1-74.9%) for individuals in the lowest tertile with stage I lung cancer. Conclusion: These results suggest that in patients undergoing treatment for stage I lung cancer, serum selenium levels at the time of diagnosis (>69 µg/L) may be associated with improved overall survival.]]> Wed 12 Aug 2020 11:14:43 AEST ]]> Serum concentrations of selenium and copper in patients diagnosed with pancreatic cancer /manager/Repository/uon:23842 Wed 11 Apr 2018 14:23:39 AEST ]]> Can selenium levels act as a marker of colorectal cancer risk? /manager/Repository/uon:14831 Wed 11 Apr 2018 13:24:36 AEST ]]> Smoking related cancers and loci at chromosomes 15q25, 5p15, 6p22.1 and 6p21.33 in the Polish population /manager/Repository/uon:13891 Wed 11 Apr 2018 12:00:00 AEST ]]> Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer? /manager/Repository/uon:24833 A, del5395, I157T), NBS1 (657del5) and PALB2 (509-510delGA, 172-175delTTGT). A statistically significant association between the 657del5 mutation and an increased risk of pancreatic cancer was observed for NBS1 gene. The Slavic NBS1 gene mutation (657delACAAA) was detected in 8 of 383 (2.09%) unselected cases compared with 22 of 4,000 (0.55%) controls (OR: 3.80, p = 0.002). The PALB2 509_510delGA and 172-175delTTGT mutations combined were seen in 2 (0.52%) unselected cases of PaCa and in 8 (0.20%) of 4,000 controls (OR: 2.61, p = 0.49). For BRCA1, the three mutations combined were detected in 4 of 383 (1.04%) PaCa patients and in 17 of 4,000 (0.42%) controls (OR: 2.46, p = 0.20). CHEK2 mutations were not associated with the risk of pancreatic cancer (OR: 1.11, p = 0.72). The founder mutation in NBS1 (657del5) was associated with an increased risk of PaCa in heterozygous carriers, indicating that this mutation appears to predispose to cancer of the pancreas. By identifying pancreatic cancer risk groups, founder mutation testing in Poland should be considered for people at risk for PaCa.]]> Sat 24 Mar 2018 07:15:11 AEDT ]]>